Results 321 to 330 of about 154,650 (346)
Some of the next articles are maybe not open access.

Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial

Nature Medicine, 2021
S. Harrison   +12 more
semanticscholar   +1 more source

[Adipocitokines and nonalcoholic steatohepatitis].

Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi, 2010
Nonalcoholic steatohepatitis is one of the most common liver diseases. It is part of the nonalcoholic fatty liver disease, which ranges from simple hepatic steatosis to necroinflammation and fibrosis of various degrees, so that many patients can evolve towards advanced liver disfunction and even cirrhosis. Insulin resistance is the main factor involved
Cristina, Lăcătuşu   +4 more
openaire   +2 more sources

Nonalcoholic Steatohepatitis: The Role of Peroxisome Proliferator-Activated Receptors

Nature Reviews Gastroenterology and Hepatology, 2021
Frank Tacke   +2 more
exaly  

Resmetirom for nonalcoholic steatohepatitis

Journal of Managed Care & Specialty Pharmacy, 2023
Shahariar Mohammed, Fahim   +9 more
openaire   +2 more sources

A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis

New England Journal of Medicine, 2021
Philip Newsome   +2 more
exaly  

Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)

Nature reviews. Drug discovery
Albert Do, Frhaan Zahrawi, W. Mehal
semanticscholar   +1 more source

Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis.

Gastroenterology, 2015
E. Vilar-Gomez   +8 more
semanticscholar   +1 more source

DT-109 Ameliorates Nonalcoholic Steatohepatitis in Nonhuman Primates

Cell Metabolism, 2023
Yuqing Eugene Chen   +2 more
exaly  

Non-Alcoholic Steatohepatitis: Emerging Molecular Targets and Therapeutic Strategies

Nature Reviews Drug Discovery, 2016
Giovanni Musso   +2 more
exaly  

Home - About - Disclaimer - Privacy